Ocugen announces publication of positive paediatric phase 2/3 study results in children aged 2-18 years for Covid-19 vaccine Covaxin in the Lancet

Ocugen Inc a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, announced the publication of positive paediatric phase 2/3 study results in children aged 2